Literature DB >> 6113284

Synthesis and anxiolytic activity of 6-(substituted-phenyl)-1,2,4-triazolo[4,3-b]pyridazines.

J D Albright, D B Moran, W B Wright, J B Collins, B Beer, A S Lippa, E N Greenblatt.   

Abstract

The synthesis of a series of 6-(substituted-phenyl)-1,2,4-triazolo[4,3-b]pyridazines (VIII) is reported. Some of these derivatives show activity in tests predictive of anxiolytic activity [(a) protection against pentylenetetrazole-induced convulsions; (b) thirsty rat conflict procedure]. They also represent a new class of compound which inhibits [3H]diazepam binding. Structure--activity correlations, as well as the ability of structures VIII to inhibit [3H]diazepam binding (in vitro), are discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6113284     DOI: 10.1021/jm00137a020

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Targeting LIN28B reprograms tumor glucose metabolism and acidic microenvironment to suppress cancer stemness and metastasis.

Authors:  Chong Chen; Lipeng Bai; Fengqi Cao; Shengnan Wang; Huiwen He; Mingcheng Song; Huilin Chen; Yan Liu; Jian Guo; Qin Si; Yundi Pan; Ruizhe Zhu; Tsung-Hsien Chuang; Rong Xiang; Yunping Luo
Journal:  Oncogene       Date:  2019-02-11       Impact factor: 9.867

2.  The active analog approach applied to the pharmacophore identification of benzodiazepine receptor ligands.

Authors:  S Tebib; J J Bourguignon; C G Wermuth
Journal:  J Comput Aided Mol Des       Date:  1987-07       Impact factor: 3.686

3.  Use of 4-bromo pyridazine 3,6-dione for building 3-amino pyridazine libraries.

Authors:  Martine Schmitt; João X de Araújo-Júnior; Said Oumouch; Jean-Jacques Bourguignon
Journal:  Mol Divers       Date:  2006-07-29       Impact factor: 2.943

4.  A 7-phenyl substituted triazolopyridazine has inverse agonist activity at the benzodiazepine receptor site.

Authors:  K Biziere; J J Bourguignon; J P Chambon; M Heaulme; A Perio; S Tebib; C G Wermuth
Journal:  Br J Pharmacol       Date:  1987-01       Impact factor: 8.739

5.  Synthesis and Bioevaluation of 3,6-Diaryl-[1,2,4]triazolo[4,3-b] Pyridazines as Antitubulin Agents.

Authors:  Qile Xu; Yueting Wang; Jingwen Xu; Maolin Sun; Haiqiu Tian; Daiying Zuo; Qi Guan; Kai Bao; Yingliang Wu; Weige Zhang
Journal:  ACS Med Chem Lett       Date:  2016-10-17       Impact factor: 4.345

6.  Scope and limitation of propylene carbonate as a sustainable solvent in the Suzuki-Miyaura reaction.

Authors:  Andrea Czompa; Balázs László Pásztor; Jennifer Alizadeh Sahar; Zoltán Mucsi; Dóra Bogdán; Krisztina Ludányi; Zoltán Varga; István M Mándity
Journal:  RSC Adv       Date:  2019-11-20       Impact factor: 4.036

7.  Beta-carboline binding indicates the presence of benzodiazepine receptor subclasses in the bovine central nervous system.

Authors:  K J Fehske; I Zube; H O Borbe; U Wollert; W E Müller
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-05       Impact factor: 3.000

8.  Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.

Authors:  Amanda P Skoumbourdis; Christopher A Leclair; Eduard Stefan; Adrian G Turjanski; William Maguire; Steven A Titus; Ruili Huang; Douglas S Auld; James Inglese; Christopher P Austin; Stephen W Michnick; Menghang Xia; Craig J Thomas
Journal:  Bioorg Med Chem Lett       Date:  2009-01-23       Impact factor: 2.823

9.  Lin28A/let-7 oncogenic circuit is a potential therapeutic target in neurocutaneous melanosis-associated CNS tumors in children.

Authors:  Mohit Jain; Son Tran; Satbir Thakur; Yoji Nagashima; Ronald Anderson; Aru Narendran
Journal:  Neurooncol Adv       Date:  2020-12-09

10.  C1632 suppresses the migration and proliferation of non-small-cell lung cancer cells involving LIN28 and FGFR1 pathway.

Authors:  Jing-Yi Chen; Yu-Jing Chen; Lu Liu; Xiang-Xiang Jin; Zhe Shen; Wen-Bin Chen; Teng Yang; Si-Bei Xu; Guang-Bao Wang; Yi-Nuo Cheng; De-Zhi Cheng; Zhi-Guo Liu; Xiao-Hui Zheng
Journal:  J Cell Mol Med       Date:  2021-12-16       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.